MaxCyteMXCT -2.36%62 Days Payable is 75.52 as of Mar. 2026, which is 55% below its 10-year median of 166.05. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, MaxCyte ranks better than 59.37% on this metric.
MaxCyte's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.30 Mil. MaxCyte's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.57 Mil.
Hence, MaxCyte's Days Payable for the
three
months ended in Mar. 2026 was 75.52.
The historical rank and industry rank for MaxCyte's Days Payable or its related term are showing as below:
MXCT'
s Days Payable Range Over the Past 10 Years
Min: 39.83 Med: 166.05 Max: 942.77
Current: 85.5
During the past 13 years, MaxCyte's highest Days Payable was 942.77. The lowest was 39.83. And the median was 166.05.
MXCT's Days Payable is ranked better than 59.37% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs MXCT: 85.50
MaxCyte's Days Payable
declined
from Mar. 2025 (110.85) to Mar. 2026 (75.52).
It may suggest that MaxCyteaccelerated paying its suppliers.
MaxCyte Days Payable Related Terms
MaxCyte Days Payable Historical Data
* Premium members only.
The historical data trend for MaxCyte's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Days Payable distribution charts can be found below:
* The bar in red indicates where MaxCyte's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
MaxCyte's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a Days Payable of 75.52 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MaxCyte and its competitors. This is 55% below median its historical median of 166.05. Over the past decade, MaxCyte's Days Payable has ranged from 39.83 to 942.77. According to the industry distribution chart, MaxCyte ranks #323 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 40.6%.
Is MaxCyte's Days Payable too high?
MaxCyte's current Days Payable of 75.52 is 55% below median its 10-year median of 166.05. Over the past 10 years, this metric has ranged from a low of 39.83 to a high of 942.77. The Medical Devices & Instruments industry median Days Payable is 67.87. MaxCyte's value of 75.52 is 11.3% above this industry median. Based on the distribution chart, MaxCyte ranks #323 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Days Payable compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #323 out of 795 companies for Days Payable. This puts MaxCyte in the upper half of its industry. The industry median Days Payable is 67.87. MaxCyte's value of 75.52 is 11.3% above this benchmark. Historically, MaxCyte's own Days Payable has ranged from 39.83 to 942.77 over the past decade. While the company's 10-year median is 166.05 vs. the industry median of 67.87, MaxCyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Days Payable of 75.52 is 11.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Days Payable is 75.52, which is 55% below median its own 10-year median of 166.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.25 — trading 51.4% below its estimated fair value. The current Days Payable is 75.52, which is 55% below median its 10-year median of 166.05 and 11.3% above the Medical Devices & Instruments industry median of 67.87. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For MaxCyte (MXCT), the current Days Payable is 75.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.25 is trading 51.4% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Days Payable: 75.52 (55% below median its 10-year median of 166.05)
GF Value™: $2.57 vs. price of $1.25 (51.4% below fair value)
Industry Position: 11.3% above the Medical Devices & Instruments median (#323 of 795)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
